Here’s how the FDA’s review of epilepsy drug could affect CBD companies

It’s shaping up to be a watershed summer for the cannabis industry with the U.S. Food and Drug Administration poised to approve the first drug made from the plant.

The agency's impending decision on Epidiolex, an epilepsy treatment made of CBD extracted from cannabis flower, could upend decades of government insistence that the plant has no medicinal value.

Here’s how the FDA’s review of epilepsy drug could affect CBD companies is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs